# Collaborative Pediatric Critical Care Research Network - Clinical Site

> **NIH NIH RL1** · BAYLOR COLLEGE OF MEDICINE · 2024 · $158,895

## Abstract

PROJECT SUMMARY/ABSTRACT – Baylor College of Medicine/Texas Children’s Hospital
The goals of the current proposal are to reorganize and expand the Collaborative Pediatric Critical Care 
Research Network (CPCCRN), to mentor young investigators in CPCCRN to become independent 
investigators, and to implement the multi-center randomized controlled “Personalized Immunomodulation in 
Sepsis-Induced Multiple Organ Dysfunction” interventional trial. The newly organized CPCCRN will expand 
from 7 to 24 clinical sites (12 Primary and 12 Ancillary sites), which will be the largest NIH Pediatric Critical 
Care Research Network to date. We at Baylor College of Medicine (BCM) - Texas Children’s Hospital (TCH; 
Primary Site) and Children’s Hospital of San Antonio (CHofSA; Ancillary Site) are very enthusiastic about 
participating as new sites. TCH is the largest freestanding children’s hospital system in the U.S. and is one of 
the best (Rank #4 Children’s Hospital by U.S. News & World Report 2020-2021). We have every pediatric 
subspecialty and offer every service expected in a quaternary pediatric center. We have an extensive track 
record of successful collaboration in multi-center clinical trials such as the Pediatric Acute Lung Injury and 
Sepsis Investigators and the Pediatric Heart Network. In combination with our CHofSA partner, we will provide 
access to 163+24 beds with 6000 annual admissions, enabling us to participate fully in the “Personalized 
Immunomodulation in Sepsis-induced Multiple Organ Dysfunction (MODS)” trial described in the Overall 
Component of this application. Our sites have several highly talented young faculty, who have career 
development grants with innovative translational research projects, and will contribute to the success of 
CPCCRN. For example, Dr. Desai (K12 recipient) pioneered the field of pediatric cirrhotic cardiomyopathy and 
bile acid-myocardial interaction (cholecardia). His aim is to improve outcomes of pediatric liver failure through 
decreasing circulating pathologic bile acids by novel bile acid sequestrants and blood purification techniques. 
Dr. Lam (K08 recipient) develops novel protein to attenuate inflammation through inhibiting leukocyte-platelet-endothelial interactions. His aim is to improve outcomes in pediatric liver failure and more recently, COVID19-
induced inflammation. Dr. Nguyen, our Co-Investigator, is R01 funded to study mechanisms of sepsis-induced 
MODS and to develop targeted novel agent for this deadly disease. His aim is to obtain Investigational New 
Drug status for his novel A2 Protein from the Food and Drug Administration, and subsequently, to enter A2 
Protein in clinical trials such as CPCCRN. Dr. Arikan, our site Principle Investigator, plans to study the impact 
of extracorporeal therapies in immunomodulation and pharmacokinetics of novel therapeutics to build on her 
previous work in pediatric MODS with a special emphasis on interaction of acute kidney injury, acquired 
immune dy...

## Key facts

- **NIH application ID:** 10900760
- **Project number:** 5RL1HD107780-04
- **Recipient organization:** BAYLOR COLLEGE OF MEDICINE
- **Principal Investigator:** Ayse Akcan Arikan
- **Activity code:** RL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $158,895
- **Award type:** 5
- **Project period:** 2021-08-18 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10900760

## Citation

> US National Institutes of Health, RePORTER application 10900760, Collaborative Pediatric Critical Care Research Network - Clinical Site (5RL1HD107780-04). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10900760. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*